Drug General Information (ID: DDITBD49A1)
Drug Name			Mitomycin		Drug Info		Ocrelizumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antineoplastics				Antineoplastics

Mechanism of Mitomycin-Ocrelizumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Mitomycin				Ocrelizumab
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Mitomycin and Ocrelizumab

Recommended Action
Management		The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.

References
1	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.